US20160069867A1 - Method for screening skin barrier function enhancing agent based on epidermal serine racemase and/or d-serine level, and skin barrier function evaluation method - Google Patents

Method for screening skin barrier function enhancing agent based on epidermal serine racemase and/or d-serine level, and skin barrier function evaluation method Download PDF

Info

Publication number
US20160069867A1
US20160069867A1 US14/477,213 US201414477213A US2016069867A1 US 20160069867 A1 US20160069867 A1 US 20160069867A1 US 201414477213 A US201414477213 A US 201414477213A US 2016069867 A1 US2016069867 A1 US 2016069867A1
Authority
US
United States
Prior art keywords
serine
barrier function
skin barrier
racemase
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/477,213
Inventor
Yosuke Tojo
Masato lino
Chieko Mizumoto
Yuzo Yoshida
Hisashi Mori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to US14/477,213 priority Critical patent/US20160069867A1/en
Assigned to SHISEIDO COMPANY, LTD. reassignment SHISEIDO COMPANY, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IINO, MASATO, MIZUMOTO, CHIEKO, MORI, HISASHI, TOJO, YOSUKE, YOSHIDA, YUZO
Priority to PCT/JP2015/056570 priority patent/WO2015133591A1/en
Priority to KR1020167024424A priority patent/KR20160127751A/en
Priority to US15/123,274 priority patent/US10337064B2/en
Publication of US20160069867A1 publication Critical patent/US20160069867A1/en
Priority to US16/412,993 priority patent/US10907208B2/en
Priority to US17/130,886 priority patent/US20210189487A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/968—Plasmin, i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Definitions

  • the present invention relates to a method for screening a skin barrier function enhancing agent, and to a method for evaluating a skin barrier function for skin.
  • Factors for increasing skin barrier function include methods of increasing the amount of intercellular lipids or arranging their orientation, and drugs such as disclosed in PTL 1 have been developed that promote production of intercellular lipids.
  • Indicators for skin barrier function include transepidermal water loss (TEWL) and the degree of penetration into skin using an indicator substance such as a pigment.
  • Skin TEWL can be measured using an apparatus such as a Vapometer, but because measurement of moisture content is an unstable indicator easily affected by the measuring environment including atmospheric moisture content and air flow, as well as the body temperature, mental state and perspiration of the subject, it has been desired to devise methods allowing more stable evaluation of skin barrier function.
  • the degree of penetration of an indicator substance is to be used as the indicator of skin barrier function, the pigment or other indicator substance must be applied onto the skin, creating a significant burden on the skin.
  • TEWL the indicator of skin barrier function for in vivo experimentation
  • screening methods include methods of using isolated skin to measure endogenous factors in skin that contribute to recovery and enhancement of barrier function, and evaluating the degree of recovery and enhancement of barrier function, but because of the lack of appropriate factors allowing convenient evaluation with small specimens, it has been a goal to identify such factors.
  • D-serine is localized in the cerebrum and hippocampus and functions as an NMDA receptor co-agonist, and it has been found to play a role in excitatory neurotransmission control (NPL 1). Also, D-aspartic acid is localized in the testis and pineal body and has been found to contribute to control of hormone secretion. Results of recent research on D-amino acids have also further demonstrated that D-serine, D-aspartic acid, D-alanine, D-glutamic acid and D-proline are present in the dermis and epidermis, and are reduced with aging (NPL 2).
  • D-serine is the D-amino acid with the highest content in the epidermis and stratum corneum, and while one role played by D-serine in the skin has been found to be alleviation of ultraviolet damage in dermal fibroblasts (PTL 2), its role in the epidermis where it is present in a higher content remains unknown.
  • Amino acid racemases are known as enzymes involved in production of D-amino acids, and they are classified into enzymes dependent on pyridoxalphosphoric acid (PLP) and racemases that do not require cofactors.
  • PLP pyridoxalphosphoric acid
  • NPL 3 a mammal-dependent serine racemase is present in mammals
  • D-serine is localized in the cerebrum and hippocampus
  • expression of serine racemase in the brains of mammals including humans has been confirmed, but there have been almost no reports of its expression in other tissues (NPL 3).
  • D-serine contributes to skin barrier function. Based on this knowledge, it has become possible to provide a method for screening drugs having effects of increasing skin barrier function by using D-serine levels, as well as levels of expression and activity of serine racemase that produces D-serine from L-serine in keratinocytes as an indicator, and also to evaluate skin barrier function enhancement in a convenient and stable manner with low burden on subjects, whereupon the present invention has been completed. By using the screening method, it has become possible to screen for drugs that enhance skin barrier function.
  • a method for screening a skin barrier function enhancing agent wherein an activity or expression level of serine racemase and/or D-serine level in keratinocytes is used as an indicator.
  • a serine racemase activating agent comprising one or more substances selected from the group consisting of hydrolyzed oat protein, Lempuyang extract, and Elephantopus mollis extract as an active ingredient, which is obtained by the screening method according to any one of [1] to [6].
  • a method for evaluating the skin barrier function wherein an activity or expression level of serine racemase and/or D-serine level from a skin sample isolated from human skin is used as an indicator.
  • determining the skin barrier function of the subject from the activity or expression level of serine racemase and/or D-serine level.
  • the skin barrier function evaluation method of the invention allows determining skin barrier function at the cellular level or tissue level, or at the biochemical level.
  • FIG. 1A shows a comparison of free L-serine levels in skin in a high-TEWL group and a low-TEWL group.
  • FIG. 1B shows a comparison of free D-serine levels in skin in a high-TEWL group and a low-TEWL group.
  • FIGS. 2A and 2B are chromatograms for detection of intracellular D-serine before and after differentiation-inducing stimulation of cultured keratinocytes.
  • FIG. 3A is a graph showing increase in free D-serine levels by hydrolyzed oat protein solution, which is one of candidate drugs.
  • FIG. 3B is a graph showing increase in serine racemase expression by hydrolyzed oat protein solution, which is one of candidate drugs.
  • the present invention relates to a method for screening skin barrier function enhancing agents, using an indicator, or a combination of two or more indicators among serine racemase expression level, activity and D-serine level in keratinocytes.
  • skin barrier function means the function of the skin that retains moisture and prevents infiltration of foreign matter from the exterior, and the function is performed by the epidermis and especially by the stratum corneum.
  • the skin barrier function can be measured by transepidermal water loss (TEWL), with higher moisture evaporation considered to be a lower skin barrier function.
  • TEWL transepidermal water loss
  • Enhancement of skin barrier function can be achieved, for example but not limited to, by increasing the number of layers of the stratum corneum, maturing the cornified envelope in the stratum corneum or increasing intercellular lipids, such as cholesterol and ceramide.
  • lipids such as cholesterol and ceramide.
  • a candidate drug provided to the screening method of the invention can be any compounds, such as a compound obtained from a combinatorial library, or a mixture or extract.
  • candidate drugs that may be used include libraries of compounds, mixtures, or extracts of food materials, cosmetic materials or pharmaceutical materials.
  • the drugs considered to have skin barrier function enhancing effects according to the present invention can be applied in foods such as functional foods and nutritious foods, cosmetics, pharmaceuticals, or quasi drugs.
  • cosmetics in which they may be applied include, for example but not limited to, cosmetic waters, creams, latexes, gels, essences, ointments, packs, bath additives, body soaps, shampoos, rinses, foundations and the like.
  • a pharmaceutical or quasi drug may be in the form of any of various ointments or creams for transdermal administration, or in a form for oral administration.
  • serine racemase expression level or activity and/or D-serine level in keratinocytes are used as an indicator.
  • Use as an indicator means that the serine racemase expression level or activity, and/or D-serine level, is the factor to be considered.
  • the screening method of the invention encompasses selection of a drug having a skin barrier function-enhancing effect based on serine racemase expression level or activity, and/or D-serine level as the judgment criteria.
  • Keratinocytes are cells constituting approximately 95% of the epidermis. Keratinocyte stem cells are present in the basal lamina of the epidermis in the body, and they migrate to the outside as they mature, thereby forming the stratum spinosum, granular layer and stratum corneum. Keratinocytes change their characteristics as they mature. The cells in the stratum spinosum or granular layer become flattened, lipids such as ceramides are released into the intercellular space, and then enucleation is occurred in the stratum spinosum of the outermost layer. This maturation process can be considered differentiation of keratinocytes. The enucleated cells lose their cytomorphology and become superposed, thereby forming the stratum corneum, and are eventually shed off as scales from the outermost layer.
  • the cultured keratinocytes to be used for the invention may be cells obtained from the epidermal basal lamina, stratum spinosum, granular layer or stratum corneum, or cells that have been induced to differentiate from stem cells such as skin epithelial stem cells or pluripotent stem cells, for example, ES cells, iPS cells, EG cells, etc.
  • Cells obtained from the epidermis and cultured may be primary cultured cells, subcultured cells, or even cancerized or immortalized cells.
  • the cultured keratinocytes to be used for the invention may also be an established keratinocyte line derived from a human or animal. Such keratinocyte cell lines can be obtained from authorized institutions or distributors.
  • the cultured product may refer to the desired cells alone, or it may also contain other cells or it may be composed of the cells and the culture medium.
  • cultured keratinocytes may refer to the keratinocytes alone, or to a combination of the keratinocytes with other cells, or to culture medium with the keratinocytes alone or with the keratinocytes and other cells.
  • Such a cultured product may include a monolayer cultured product, mixed cultured product or three-dimensional cultured product.
  • the culture medium in which the keratinocytes are cultured may include any desired culture medium so long as it allows to culture keratinocytes, for example not limited to, HuMedia-KB2 (Kurabo Industries, Ltd.) or Keratinocyte-SFM (Invitrogen Corp.) medium with addition of various additives may be used.
  • the culturing conditions will usually be at 37° C. in the presence of 5% CO 2 , with variation in a range that permits proliferation of keratinocytes.
  • the culture medium is preferably in an L-serine-enriched state, from the viewpoint of using D-serine abundance as an index of serine racemase activity.
  • culture medium obtained by adding an HuMedia-KG proliferating additive set to HuMedia-KB2 (Kurabo Industries, Ltd.) has the 100-fold or greater abundance of L-serine with respect to D-serine.
  • the keratinocytes cultured product has been cultured after seeding, and the keratinocytes cultured product being about 50% confluency toconfluent can be subjected to experiment.
  • the confluency is preferably 70% or greater and even more preferably 80% or greater, from the viewpoint of inducing differentiation.
  • the process for adding a candidate drug to the cultured keratinocytes may involve exchanging the culture medium for the cultured keratinocytes with a culture medium containing the candidate drug, or adding the candidate drug, either directly or as a diluted solution, to the cultured product containing the keratinocytes and the culture medium.
  • Serine racemase is a racemase that is dependent on pyridoxal-5′ phosphate (PLP), a coenzyme of vitamin B6. While it is not intended to be constrained by theory, serine racemase is an enzyme capable of conversion between L-serine and D-serine via production of an anionic intermediate, by withdrawal of the ⁇ -hydrogen from serine. In the conversion reaction between L-serine and D-serine, there is no change in enthalpy before and after the reaction, and the reaction is driven by entropy. Therefore, L-serine and D-serine are equivalent in the equilibrium state.
  • PRP pyridoxal-5′ phosphate
  • the racemase can be identical to the racemase found to be expressed in the brain according to NPL 3, or a homolog or ortholog thereof. Thus, it can be amplified by a primer pair used in that publication, and is detectable by the racemase antibody described in the same publication.
  • Serine racemase can be identified by a person skilled in the art according to animal species, from the web site of an authorized institution such as NCBI.
  • serine racemase activity in keratinocytes can be used as an indicator for evaluation of skin barrier function or for screening of skin barrier function enhancing agents.
  • Serine racemase activity can generally be based on the amount of D-serine produced by conversion of L-serine in the culture medium, when a substance acting as the substrate for the enzyme is not added, or it may be based on the total amount of other D-amino acids including D-serine.
  • addition of a substance other than serine that can serve as a substrate for serine racemase may be carried out to measure the amount of product or measure the conversion efficiency, based on conversion of the additive.
  • serine racemase activity When serine racemase activity is to be measured based on the D-serine level, it may be determined by the abundance of D-serine in a skin sample isolated from a subject, or in cultured keratinocytes, i.e. in a culture medium, cells or both, or it may be determined by an enzymatic parameter determined based on the change in the abundance of D-serine in a skin sample or in cultured keratinocytes. This method is applicable to all of the aforementioned substances that can act as enzyme substrates.
  • the enzymatic parameter representing serine racemase enzyme activity may be obtained by determining the V max or K m values.
  • the D-serine level in keratinocytes can be used as an indicator for evaluation of skin barrier function or for screening of skin barrier function enhancing agents.
  • the D-serine level may be measured in a skin sample isolated from a subject, or in cultured keratinocytes, i.e. in a culture medium, cells or both.
  • the method of measuring the D-serine level may be carried out using a known method. For example, it may be carried out by an HPLC method using an optical isomer separating column, or a gas chromatography, electrophoresis or enzyme method.
  • L-serine When measurement of the serine racemase activity is carried out by measuring the D-serine level, L-serine may be added to the cultured keratinocytes to increase the D-serine level.
  • serine racemase catalyzes conversion reaction between L-serine and D-serine, the enthalpy before and after the reaction does not change, and the reaction is driven by entropy. Therefore addition of L-serine can increase the D-serine level in proportion to the serine racemase activity, and therefore measurement of the D-serine level becomes easier.
  • serine racemase expression level can be used as an indicator for evaluation of skin barrier function or for screening of skin barrier function enhancing agents.
  • the serine racemase expression level can be determined by measuring serine racemase protein by an immunological method using anti-serine racemase antibody.
  • the immunological method can be carried out by Western blotting, fluorescent immunostaining or ELISA.
  • the anti-serine racemase antibody used may be monoclonal antibody or polyclonal antibody, and it may be antibody collected by immunizing an experimental animal such as a rabbit or mouse with serine racemase protein or antigen peptide.
  • the mRNA may be measured by any desired method, and for example, it can be measured based on a quantitative PCR method.
  • a quantitative PCR method is usually conducted as follows, with the understanding that this is not limitative.
  • the mRNA is extracted from collected cells, and cDNA is prepared using polyT primer and reverse transcriptase.
  • the prepared cDNA may be subjected to the SYBR green method or fluorogenic probe method to quantify the amount of mRNA in the cells.
  • the screening method of the invention may comprise the following steps:
  • the screening method of the invention may further comprise a step of inducing differentiation of keratinocytes.
  • the differentiation inducing step is carried out by subjecting keratinocytes to differentiation-inducing stimulation.
  • Subjecting keratinocytes to differentiation-inducing stimulation results in cellular flattening, increase in intracellular fibers or granules, indistinct intercellular spaces, superpositioning (especially with monolayer cultures), and finally resulting in the morphological change of enucleation, or changes in cells that result in production of or changes in proteins such as keratin 1, keratin 10, involucrin or transglutaminase activation (see Nippi Kaishi, 90(12), 1089-1101, http://drmtl.org/data/090121089.pdf, Drug News Perspect 2004, 17(2) p 117).
  • the differentiation-inducing stimulation may be any desired stimulation that can produce the aforementioned differentiation of keratinocytes, and may include, for example, stimulation of calcium ion that increases the calcium ion concentration, stimulation with phorbol-12-myristate-13-acetate (Hawley-Nelson P, Stanley J R et al, Exp Cell Res, 137: 155-167, 1982), physical stimulation by voltage or gas phase exposure, or stimulation with a biological solution.
  • a calcium salt or its diluted solution may be added to a concentration of 0.1 mM to 10 mM as the final concentration of calcium ion, or the culture medium may be exchanged with medium already adjusted to a final concentration of calcium ion.
  • the calcium salt used includes, for example, calcium chloride, calcium hydrogencarbonate, calcium carbonate, calcium nitrate or calcium acetate, etc.
  • the upper limit for the final calcium ion concentration is preferably 5 mM and even more preferably 2 mM, from the viewpoint of not adversely affecting the cell culture. From the viewpoint of promoting the induced differentiation, the lower limit for the concentration is preferably 0.5 mM and more preferably 1.0 mM.
  • the differentiation-inducing step and the candidate drug addition step may be carried out simultaneously, the candidate drug addition step may be carried out after the differentiation-inducing step, or conversely the differentiation-inducing step may be carried out after the candidate drug addition step.
  • the timing for inducing differentiation and adding candidate drugs can be varied depending on the action mechanism desired for the candidate drug.
  • the addition step is preferably carried out either simultaneously with or before the stimulation step.
  • the addition step is preferably carried out simultaneously with or after the stimulating step, and from the viewpoint of illuminating mechanisms such as exploring mechanisms such as pre-blocking of receptors on which differentiation-inducing stimulation acts, the stimulating step is preferably carried out after the addition step.
  • a cell culturing step of several minutes to several hours may be included between the addition step and the stimulation step.
  • a cell culturing step may be further included before the step of measuring the serine racemase expression level or activity and/or the D-serine level.
  • the period for the cell culturing step can be selected as desired depending on the type and concentration of the differentiation-inducing agent used and the type of keratinocytes, and culturing may be conducted for 6 hours to 1 week, for example. From the viewpoint of adequately expressing serine racemase, the minimum culturing period is preferably 12 hours and more preferably 1 day.
  • the maximum culturing period cannot be specified since it will differ depending on the culturing method, such as monolayer culturing, multi-layered culturing or three-dimensional culturing, but from the viewpoint of maintaining normal cell culturing conditions it is preferably no longer than one week and more preferably no longer than 3 days, for monolayer culturing.
  • the screening method of the invention may further include a damage-inducing step.
  • the damage-inducing step may be inducement of damage by physical or chemical stimulation of the cultured keratinocytes, such as addition of a radical source such as ultraviolet irradiation or an oxidizing agent, addition of a surfactant, or exchange with oligotrophic medium.
  • a radical source such as ultraviolet irradiation or an oxidizing agent
  • addition of a surfactant or exchange with oligotrophic medium.
  • the keratinocytes that have been damaged by the damage-inducing step may be expected to have reduced serine racemase expression.
  • the candidate drug in a screening method in which a damage-inducing step is carried out after the candidate drug addition step, if reduction in racemase expression level or racemase activity and/or D-serine level is found to be suppressed, the candidate drug can be used as a preventive drug against damage to skin barrier function.
  • the candidate drug in a screening method in which a candidate drug addition step is carried out after a damage-inducing step, if reduced racemase expression level or racemase activity and/or D-serine level is found to be increased, the candidate drug can be used as a restoring, ameliorating or curative agent for skin barrier function.
  • a candidate drug that increases racemase expression level or racemase activity, and/or D-serine level can be considered to be an enhancer of skin barrier function.
  • hydrolyzed oat protein, Lempuyang extract, Elephantopus mollis extract can be selected as an agent enhancing skin barrier function.
  • an agent is not limited to extract derived from Lempuyang and Elephantopus mollis
  • extract derived from related species has the skin barrier function enhancing effect in a similar way.
  • the skin barrier function enhancing agent of the present invention include extract of a plant belonging to the genus Zingiber of Zingiberaceae family and a plant belonging to the Elephamtopus genus of Compositae family. Therefore, a cosmetic product exerting skin barrier function enhancing effect can be prepared by containing these substances in a cosmetic product.
  • the hydrolyzed oat protein used in the present invention is a hydrolyzate of protein obtained from oat ( Avena sativa L.). While the protein of oat is extracted, for example, from seeds, leaves, roots, and from bran, the seeds are particularly preferred.
  • the oat which was immediately dried and ground after harvest, are preferred. It may be dried under the sun, or may be dried by using a drying machine that is normally used.
  • the protein is hydrolyzed by the acid or enzyme treatment in the process of extraction or after extraction. Oats is a plant that is grown for food from West Asia to Europe and North America.
  • the extraction solvent used in the present invention can be any solvent usually used for extraction. In particular, an organic solvent including alcohols such as methanol, ethanol, water-containing alcohols, acetone, ethyl acetate ester can be used for extraction alone or in combination. It is possible to perform the extraction with water.
  • the amount of the hydrolyzed oat protein of the present invention can be arbitrarily selected by a person skilled in the art within the scope exerting an effect.
  • the amount of the extract constitutes, as a dry composition, 0.0005-20.0 wt % of the total amount of the external formula
  • the upper limit of the amount is preferably less than 10 wt % by weight or less, and more preferably 5 wt % or less from the viewpoint of exerting an effect and preparing a formulation.
  • the lower limit of the amount is preferably 0.0001 wt % or more, more preferably 0.0005 wt % or more in view of exerting a sufficient skin barrier function enhancing effect.
  • Lempuyang Zingiber aromaticum Mal.
  • the extract used in the present invention is prepared by immersing foliage, stem including rhizomes, fruits, etc., of the plant and the whole plant in an extract solvent, optionally heating the mixture to reflux, then being subjected to filtration and concentration.
  • the extraction solvent used in the present invention can be any solvent usually used for extraction.
  • an organic solvent including alcohols such as methanol, ethanol, water-containing alcohols, acetone, ethyl acetate ester can be used for extraction alone or in combination. It is possible to perform the extraction with water.
  • the amount of the extract of a plant belonging to the genus Zingiber of Zingiberaceae family can be arbitrarily selected by a person skilled in the art within the scope exerting an effect.
  • the amount of the extract constitutes, as a dry composition, 0.0005-20.0 wt % of the total amount of the external formula
  • the upper limit of the amount is preferably less than 10 wt % by weight or less, and more preferably 5 wt % or less from the viewpoint of exerting an effect and preparing a formulation.
  • the lower limit of the amount is preferably 0.0001 wt % or more, more preferably 0.0005% wt % or more in view of exerting a sufficient skin barrier function enhancing effect.
  • the extract of a plant belonging to the genus Elephamtopus of Compositae family is prepared by immersing Leaves, stems, flowers, bark, seeds or fruit, etc., of the plant and the whole plant in an extract solvent, optionally heating the mixture to reflux, then being subjected to filtration and concentration.
  • the extraction solvent used in the present invention can be any solvent usually used for extraction.
  • an organic solvent including alcohols such as methanol, ethanol, water-containing alcohols, acetone, ethyl acetate ester can be used for extraction alone or in combination. It is possible to perform the extraction with water.
  • the amount of the extract of a plant belonging to the genus Elephamtopus of Compositae family can be arbitrarily selected by a person skilled in the art within the scope exerting an effect.
  • the amount of the extract constitutes, as a dry composition, 0.0005-20.0 wt % of the total amount of the external formula
  • the upper limit of the amount is preferably less than 10 wt % by weight or less, and more preferably 5 wt % or less from the viewpoint of exerting an effect and preparing a formulation.
  • the lower limit of the amount is preferably 0.0001 wt % or more, more preferably 0.0005% wt % or more in view of exerting a sufficient skin barrier function enhancing effect.
  • a step of determining the skin barrier function-enhancing function of a candidate drug based on serine racemase expression level or activity, or D-serine level it is possible to determine it based on the measured serine racemase expression level or activity and/or D-serine level using a preset table showing the relationship between expression level or activity and/or D-serine level and barrier function-enhancing function.
  • a table can be prepared using racemase expression level or activity and/or D-serine level measured by a similar experiment without the candidate drug, as a control, or using racemase expression level or activity and/or D-serine level measured by a similar experiment using a control drug known to increase serine racemase expression level or activity and/or D-serine level.
  • the skin barrier function-enhancing action of a candidate drug can be determined by setting a predetermined threshold value based on comparison with a control, and determining whether or not the effect is higher than the threshold value by a statistically significant difference.
  • a person skilled in the art can appropriately set the threshold value according to the skin barrier function-enhancing effect that is desired.
  • Such a threshold value may be a threshold value set to an arbitrary factor with respect to serine racemase expression level or activity and/or D-serine level for a control where the drug has not been added, and for example, the value may be set to a factor of 1.1, for example, by a statistically significant difference and marginal significant difference.
  • a statistically significant difference is p ⁇ 0.05, and a marginal significant difference is p ⁇ 0.1.
  • a skin barrier function-enhancing effect is exhibited in the case of high expression level or activity compared to the racemase expression level or activity and/or D-serine level measured by conducting a similar experiment without the candidate drug, as a control, in which case it can be determined that higher expression level or activity and/or D-serine level is a greater skin barrier function-enhancing effect.
  • the invention relates to a method of evaluating, judging and discriminating skin barrier function using serine racemase expression level or activity and/or D-serine level as an indicator.
  • evaluation, judgment or discrimination can be made by measuring D-serine content, serine racemase activity or serine racemase expression level for a skin sample such as a stratum corneum sample obtained by tape stripping, for example, from a subject.
  • the method of evaluating, judging or discriminating skin barrier function will usually be carried out by measuring TEWL using a Vapometer.
  • TEWL is dependent on the state of the skin and its numerical values vary depending on rinsing and abrasion, while in skin disease patients there is no definite correlation between the numerical values and skin health.
  • the evaluation, judgment and discrimination method of the invention uses serine racemase activity or expression level and/or D-serine level as an indicator to allow measurement of the original cellular-level skin barrier function of skin.
  • the evaluation method of the invention determines the normalcy of skin barrier function on the cellular level, it allows prediction of future skin barrier function rather than current skin barrier function.
  • the evaluation, judgment or discrimination of skin barrier function can be made using a table or threshold value representing the relationship between a previously set serine racemase expression level or activity and/or D-serine level, and barrier function-enhancing effect.
  • a table or threshold value can be set based on expression level or activity and/or D-serine level obtained for a skin sample obtained and isolated from subject groups with healthy skin, subject groups with roughened skin, and from age-classified subject groups.
  • the subjects were 57 volunteers having healthy test sites, and the test sites wetted by rinsing after cleaning by a prescribed method were allowed to stand for 30 minutes at constant temperature, constant humidity conditions (room temperature: 22° C., humidity: 45%).
  • TEWL transepidermal water loss
  • Vapometer Selfin Co.
  • Measurement was performed 3 times and the average value was subsequently used for analysis.
  • the stratum corneum at the TEWL-measured site was stripped twice using adhesive tape and the second was used for extraction of amino acids in a 95% methanol aqueous solution.
  • the optical isomers of the extracted amino acids were analyzed by a reported method (reference: Yurika Miyoshi et al., Journal of Chromatography B, 877 (2009) 2506-2512). The results are summarized below.
  • the extracted amino acids were subjected to fluorescent derivatization with 4-fluoro-7-nitro-2,1,3-benzooxadiazole (NBD-F) in a borate buffer (pH 8.0). After this derivatization, pH of the solution was adjusted to acidic conditions by adding trifluoroacetic acid.
  • the derivatives were subjected two-dimensional Micro HPLC (Shiseido Corp.).
  • the first dimension there was used a micro monolithic ODS column (inner diameter: 0.53 mm, full lengths: 500, 750, 1000 mm, Shiseido Corp.), and for the second dimension there was used an optical resolution enantio-selective column (inner diameter: 1.5 mm, full length: 250 mm, mobile phase conditions were optimized for each amino acid).
  • the NBD-amino acids were detected by fluorescence at 530 nm (excitation wavelength of 470 nm). The results are shown in Table 1 and FIG. 1 .
  • D-serine (D-Ser) content and skin barrier function in the stratum corneum were compared between the top 17 (inferior barrier function group) and bottom 17 (superior barrier function group).
  • the significant difference between the two groups was verified by a non-paired Student's t-test.
  • results of comparison for L-serine indicated a tendency toward lower L-serine content in the inferior barrier function group and higher L-serine content in the superior barrier function group, although the difference was not significant.
  • the high D-serine content in the superior barrier function group was not due to the amount of L-serine as the precursor, but rather to racemase expression and activity.
  • Normal human keratinocytes were seeded in a 24 well multiplate to a cell density of 2.5 ⁇ 10 4 cells/well, and cultured in KGM culture medium (Kurabo Industries, Ltd.) under conditions of 37° C., 5% CO 2 . After 3 days, the medium was exchanged with KGM culture medium to which 1.8 mM calcium chloride and 10 mM L-serine had been added (test group), or KGM culture medium to which 10 mM L-serine alone had been added (control group), and culturing was continued for another 2 days.
  • KGM culture medium Kurabo Industries, Ltd.
  • the extracted amino acids were subjected to fluorescent derivatization with 4-fluoro-7-nitro-2,1,3-benzooxadiazole (NBD-F) in a borate buffer (pH 8.0). After this derivatization, pH of the solution was adjusted to acidic conditions by adding trifluoroacetic acid.
  • the derivatives were subjected to two-dimensional Micro HPLC (Shiseido Corp.). For the first dimension there was used a micro monolithic ODS column (inner diameter: 0.53 mm, full length: 750 mm, Shiseido Corp.), and for the second dimensional optical resolution, there was used an optical resolution enantio-selective column inner diameter: 1.5 mm, full length: 250 mm, mobile phase conditions were optimized for each amino acid).
  • the NBD-amino acids were detected by fluorescence at 530 nm (excitation wavelength of 470 nm). The results for the test group and control group are shown in FIG. 2 .
  • Normal human keratinocytes were seeded in a 24 well multiplate to a cell density of 2.5 ⁇ 10 4 cells/well, and cultured in KGM culture medium (Kurabo Industries, Ltd.) under conditions of 37° C., 5% CO 2 . After 3 days, the medium was exchanged with KGM culture medium containing 1.8 mM calcium chloride, 10 mM L-serine and the candidate drug diluted solution, and culturing was continued for another 2 days. Seven drugs were used as candidate drugs, of which one was a 0.5% hydrolyzed oat protein solution.
  • the extracted amino acids were subjected to fluorescent derivatization with 4-fluoro-7-nitro-2,1,3-benzooxadiazole (NBD-F) in a borate buffer (pH 8.0). After this derivatization, pH of the solution was adjusted to acidic conditions by adding trifluoroacetic acid.
  • the derivatives were subjected to two-dimensional Micro HPLC (Shiseido Corp.). For the first dimension there was used a micro monolithic ODS column (inner diameter: 0.53 mm, full length: 750 mm, Shiseido Corp.), and for the second dimensional optical resolution, there was used an optical resolution enantio-selective column (inner diameter: 1.5 mm, full length: 250 mm, mobile phase conditions were optimized for each amino acid).
  • the NBD-amino acids were detected by fluorescence at 530 nm (excitation wavelength of 470 nm). The results are shown in Table 2 and FIG. 3A below.
  • RT-PCR was conducted with the G3PDH (glyceraldehyde-3-phosphate) gene as the internal standard in addition to the serine racemase gene, and the drug evaluation was conducted by correlating the relative expression level of serine racemase with the relative expression level of G3PDH.
  • the primers selected for use in RT-PCR were those described in NPL 3 and NPL 4. The results are shown in Table 2 and FIG. 3B below.
  • hydrolyzed oat protein solution promoted serine racemase expression in differentiation-induced keratinocytes. It was also shown that hydrolyzed oat protein solution increases the D-serine content in differentiation-induced keratinocytes. Based on these results, hydrolyzed oat protein solution can be selected as an effective drug for enhancing skin barrier function.
  • Normal human keratinocytes were seeded in a 24 well multiplate to a cell density of 2.5 ⁇ 10 4 cells/well, and cultured in KGM culture medium (Kurabo Industries, Ltd.) under conditions of 37° C., 5% CO 2 . After 3 days, the medium was exchanged with KGM culture medium containing 1.8 mM calcium chloride, 10 mM L-serine and the candidate drug diluted solution, and culturing was continued for another 2 days. 12 drugs were used as candidate drugs, in which 0.5% Lempuyang extract and 0.5% Elephantopus mollis extract were included.
  • RT-PCR was conducted with the G3PDH (glyceraldehyde-3-phosphate) gene as the internal standard in addition to the serine racemase gene, and the drug evaluation was conducted by correlating the relative expression level of serine racemase with the relative expression level of G3PDH.
  • the primers selected for use in RT-PCR were those described in NPL 3 and NPL 4. The results are shown in Table 3 below.
  • Lempuyang extract and Elephantopus mollis extract promoted serine racemase expression in differentiation-induced keratinocytes. Based on this result, Lempuyang extract and Elephantopus mollis extract can be selected as an effective drug for enhancing skin barrier function.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Birds (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)

Abstract

The object of the invention is to develop a screening method for drugs having effects of increasing skin barrier function in in vitro experimentation, and to evaluate skin barrier function for skin. Serine racemase activity and/or expression level are used as an indicator to allow screening of candidate drugs.

Description

    TECHNICAL FIELD
  • The present invention relates to a method for screening a skin barrier function enhancing agent, and to a method for evaluating a skin barrier function for skin.
    • BACKGROUND ART
  • When skin barrier function is lost, skin moisture is also lost and infiltration of exterior foreign matter occurs, creating a condition of sensitive and dry skin and skin roughening, and potentially resulting in dermatitis and allergy. From the viewpoint of developing functional foods, cosmetics and pharmaceuticals, therefore, it is desirable to develop drugs that can increase skin barrier function. Factors for increasing skin barrier function include methods of increasing the amount of intercellular lipids or arranging their orientation, and drugs such as disclosed in PTL 1 have been developed that promote production of intercellular lipids.
  • Indicators for skin barrier function include transepidermal water loss (TEWL) and the degree of penetration into skin using an indicator substance such as a pigment. Skin TEWL can be measured using an apparatus such as a Vapometer, but because measurement of moisture content is an unstable indicator easily affected by the measuring environment including atmospheric moisture content and air flow, as well as the body temperature, mental state and perspiration of the subject, it has been desired to devise methods allowing more stable evaluation of skin barrier function. When the degree of penetration of an indicator substance is to be used as the indicator of skin barrier function, the pigment or other indicator substance must be applied onto the skin, creating a significant burden on the skin.
  • In order to perform screening of drugs with effects of increasing skin barrier function from among numerous candidate drugs it is possible to use TEWL as the indicator of skin barrier function for in vivo experimentation, but this is unstable and significantly affected by the measuring environment, and it has been difficult to accomplish screening of drugs with an effect of increasing the physiological and structural skin barrier function from among numerous candidate drugs. On the other hand, such screening methods that have been considered include methods of using isolated skin to measure endogenous factors in skin that contribute to recovery and enhancement of barrier function, and evaluating the degree of recovery and enhancement of barrier function, but because of the lack of appropriate factors allowing convenient evaluation with small specimens, it has been a goal to identify such factors.
  • Almost all amino acids are known to be classified according to their enantiomeric absolute configuration, named as L-form and D-form, with the amino acids in living organisms being mainly the L-form, while D-amino acids have been thought to be found in a very limited number of biological components such as bacterial peptidoglycans. However, the results of recent research have demonstrated that various D-amino acids are to be found not only in microorganisms but also in plants and mammals, either in free form or as the amino acid residues composing proteins, and that they exhibit various types of physiological function. The firstly found free D-amino acids in mammals were D-serine and D-aspartic acid. D-serine is localized in the cerebrum and hippocampus and functions as an NMDA receptor co-agonist, and it has been found to play a role in excitatory neurotransmission control (NPL 1). Also, D-aspartic acid is localized in the testis and pineal body and has been found to contribute to control of hormone secretion. Results of recent research on D-amino acids have also further demonstrated that D-serine, D-aspartic acid, D-alanine, D-glutamic acid and D-proline are present in the dermis and epidermis, and are reduced with aging (NPL 2). D-serine is the D-amino acid with the highest content in the epidermis and stratum corneum, and while one role played by D-serine in the skin has been found to be alleviation of ultraviolet damage in dermal fibroblasts (PTL 2), its role in the epidermis where it is present in a higher content remains unknown.
  • Amino acid racemases are known as enzymes involved in production of D-amino acids, and they are classified into enzymes dependent on pyridoxalphosphoric acid (PLP) and racemases that do not require cofactors. Among reports that D-amino acids are present in eukaryotic cells including those of mammals it has been reported that PLP-dependent serine racemase is present in mammals (NPL 3), but it has not yet been confirmed whether or not aspartic acid racemase is present with racemase activity in mammals. Since D-serine is localized in the cerebrum and hippocampus, expression of serine racemase in the brains of mammals including humans has been confirmed, but there have been almost no reports of its expression in other tissues (NPL 3).
    • CITATION LIST Patent Literature
    • [PTL 1] Japanese Unexamined Patent Publication No. 2012-92032
    • [PTL 2] WO2011/030903
    Non-Patent Literature
    • [NPL 1] S. H. Snyder, et al., NeuroChem Res 25, 553 (2000)
    • [NPL 2] Y. Tojo, Food Style 21, 2013, August, (Vol. 17, No. 8)
    • [NPL 3] Molecular Brain Research, Vol. 125, pp. 96-104, 2004
    • [NPL 4] Overview of experimental protocols for development of functional cosmetic materials, CMC Publishing, 2010, p. 214-216
    DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention
  • There has been interest in increasing skin barrier function by increasing intercellular lipid levels and ordering their arrangement. On the other hand, in order to enhance and repair skin barrier function, increasing the number of healthy stratum corneum layers is thought to be an effective approach in view of increasing physiological or structural skin barrier function. However, no drugs with such effects have been known, and as mentioned above, it has been difficult to discover such drugs by screening. Accordingly, it has been desired to develop a method for screening drugs having effects of increasing physiological or structural skin barrier function.
    • Means for Solving the Problems
  • As a result of diligent research on D-serine whose function in skin has not been known, the present inventors have discovered that D-serine contributes to skin barrier function. Based on this knowledge, it has become possible to provide a method for screening drugs having effects of increasing skin barrier function by using D-serine levels, as well as levels of expression and activity of serine racemase that produces D-serine from L-serine in keratinocytes as an indicator, and also to evaluate skin barrier function enhancement in a convenient and stable manner with low burden on subjects, whereupon the present invention has been completed. By using the screening method, it has become possible to screen for drugs that enhance skin barrier function.
  • Specifically, the present inventors have completed the following invention.
  • [1] A method for screening a skin barrier function enhancing agent, wherein an activity or expression level of serine racemase and/or D-serine level in keratinocytes is used as an indicator.
  • [2] The screening method according to [1], comprising:
  • adding a candidate drug to keratinocytes;
  • measuring the activity or expression level of serine racemase and/or the D-serine level in the keratinocytes; and
  • determining the skin barrier function-enhancing effect of the candidate drug based on the expression level or activity of serine racemase and/or the D-serine level.
  • [3] The screening method according to [2], further comprising a step of inducing differentiation of the keratinocytes.
  • [4] The screening method according to [3], wherein the screening method is conducted in the differentiation-induced keratinocytes.
  • [5] The screening method according to any one of [1] to [4], wherein the measurement of the serine racemase expression level is carried out by measuring the amount of serine racemase mRNA or protein.
  • [6] The screening method according to any one of [1] to [4], wherein the measurement of serine racemase activity is carried out by measuring the substrate conversion efficiency or measuring the amount of D-amino acid product.
  • [7] A serine racemase activating agent comprising one or more substances selected from the group consisting of hydrolyzed oat protein, Lempuyang extract, and Elephantopus mollis extract as an active ingredient, which is obtained by the screening method according to any one of [1] to [6].
  • [8] A method for evaluating the skin barrier function, wherein an activity or expression level of serine racemase and/or D-serine level from a skin sample isolated from human skin is used as an indicator.
  • [9] The skin barrier function evaluation method according to [8], comprising:
  • measuring the activity or expression level of serine racemase and/or D-serine level in a skin sample isolated from a subject, and
  • determining the skin barrier function of the subject from the activity or expression level of serine racemase and/or D-serine level.
  • [10] The skin barrier function evaluation method according to [8] or [9], wherein measurement of the serine racemase expression level is carried out by measuring the amounts of serine racemase mRNA or protein.
  • [11] The method according to [8] or [9], wherein the measurement of serine racemase activity is carried out by measuring the substrate conversion efficiency by serine racemase or the amount of D-amino acid product.
    • Effect of the Invention
  • It is possible to select drugs that can improve or enhance skin barrier function by using the screening method of the invention. In addition, the skin barrier function evaluation method of the invention allows determining skin barrier function at the cellular level or tissue level, or at the biochemical level.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A shows a comparison of free L-serine levels in skin in a high-TEWL group and a low-TEWL group. FIG. 1B shows a comparison of free D-serine levels in skin in a high-TEWL group and a low-TEWL group.
  • FIGS. 2A and 2B are chromatograms for detection of intracellular D-serine before and after differentiation-inducing stimulation of cultured keratinocytes.
  • FIG. 3A is a graph showing increase in free D-serine levels by hydrolyzed oat protein solution, which is one of candidate drugs. FIG. 3B is a graph showing increase in serine racemase expression by hydrolyzed oat protein solution, which is one of candidate drugs.
    •  BEST MODE FOR CARRYING OUT THE INVENTION
  • The present invention relates to a method for screening skin barrier function enhancing agents, using an indicator, or a combination of two or more indicators among serine racemase expression level, activity and D-serine level in keratinocytes.
  • It is possible to obtain drugs having skin barrier function enhancing effects by using the screening method of the present invention. Here, “skin barrier function” means the function of the skin that retains moisture and prevents infiltration of foreign matter from the exterior, and the function is performed by the epidermis and especially by the stratum corneum. The skin barrier function can be measured by transepidermal water loss (TEWL), with higher moisture evaporation considered to be a lower skin barrier function.
  • Enhancement of skin barrier function can be achieved, for example but not limited to, by increasing the number of layers of the stratum corneum, maturing the cornified envelope in the stratum corneum or increasing intercellular lipids, such as cholesterol and ceramide. Thus, while it is not intended to be constrained by theory, it is conjectured that applying a drug selected by the screening method of the invention onto skin can enhance serine racemase expression or activity, or increase D-serine levels, resulting in an effect of an increased number of layers of the stratum corneum, thereby enhancing the skin barrier function.
  • A candidate drug provided to the screening method of the invention can be any compounds, such as a compound obtained from a combinatorial library, or a mixture or extract. Examples of candidate drugs that may be used include libraries of compounds, mixtures, or extracts of food materials, cosmetic materials or pharmaceutical materials. The drugs considered to have skin barrier function enhancing effects according to the present invention can be applied in foods such as functional foods and nutritious foods, cosmetics, pharmaceuticals, or quasi drugs. Examples of cosmetics in which they may be applied include, for example but not limited to, cosmetic waters, creams, latexes, gels, essences, ointments, packs, bath additives, body soaps, shampoos, rinses, foundations and the like. More preferably, they are applied to cosmetics for sensitive skin, such as cosmetic waters, creams, latexes, essences and the like. A pharmaceutical or quasi drug may be in the form of any of various ointments or creams for transdermal administration, or in a form for oral administration.
  • In the screening method of the invention, serine racemase expression level or activity and/or D-serine level in keratinocytes, are used as an indicator. Use as an indicator means that the serine racemase expression level or activity, and/or D-serine level, is the factor to be considered. Thus, when a candidate drug is added, the screening method of the invention encompasses selection of a drug having a skin barrier function-enhancing effect based on serine racemase expression level or activity, and/or D-serine level as the judgment criteria.
  • Keratinocytes are cells constituting approximately 95% of the epidermis. Keratinocyte stem cells are present in the basal lamina of the epidermis in the body, and they migrate to the outside as they mature, thereby forming the stratum spinosum, granular layer and stratum corneum. Keratinocytes change their characteristics as they mature. The cells in the stratum spinosum or granular layer become flattened, lipids such as ceramides are released into the intercellular space, and then enucleation is occurred in the stratum spinosum of the outermost layer. This maturation process can be considered differentiation of keratinocytes. The enucleated cells lose their cytomorphology and become superposed, thereby forming the stratum corneum, and are eventually shed off as scales from the outermost layer.
  • The cultured keratinocytes to be used for the invention may be cells obtained from the epidermal basal lamina, stratum spinosum, granular layer or stratum corneum, or cells that have been induced to differentiate from stem cells such as skin epithelial stem cells or pluripotent stem cells, for example, ES cells, iPS cells, EG cells, etc. Cells obtained from the epidermis and cultured may be primary cultured cells, subcultured cells, or even cancerized or immortalized cells. The cultured keratinocytes to be used for the invention may also be an established keratinocyte line derived from a human or animal. Such keratinocyte cell lines can be obtained from authorized institutions or distributors.
  • The cultured product may refer to the desired cells alone, or it may also contain other cells or it may be composed of the cells and the culture medium. Thus, cultured keratinocytes may refer to the keratinocytes alone, or to a combination of the keratinocytes with other cells, or to culture medium with the keratinocytes alone or with the keratinocytes and other cells. Such a cultured product may include a monolayer cultured product, mixed cultured product or three-dimensional cultured product. The culture medium in which the keratinocytes are cultured may include any desired culture medium so long as it allows to culture keratinocytes, for example not limited to, HuMedia-KB2 (Kurabo Industries, Ltd.) or Keratinocyte-SFM (Invitrogen Corp.) medium with addition of various additives may be used. The culturing conditions will usually be at 37° C. in the presence of 5% CO2, with variation in a range that permits proliferation of keratinocytes. The culture medium is preferably in an L-serine-enriched state, from the viewpoint of using D-serine abundance as an index of serine racemase activity. In most cases, D-amino acids will not be intentionally added to the culture medium, and the abundance of L-serine with respect to D-serine in the culture medium will be at least 1.1-fold, more preferably 10-fold and even more preferably 50-fold or greater. For example, culture medium (KGM culture medium) obtained by adding an HuMedia-KG proliferating additive set to HuMedia-KB2 (Kurabo Industries, Ltd.) has the 100-fold or greater abundance of L-serine with respect to D-serine.
  • The keratinocytes cultured product has been cultured after seeding, and the keratinocytes cultured product being about 50% confluency toconfluent can be subjected to experiment. The confluency is preferably 70% or greater and even more preferably 80% or greater, from the viewpoint of inducing differentiation. The process for adding a candidate drug to the cultured keratinocytes may involve exchanging the culture medium for the cultured keratinocytes with a culture medium containing the candidate drug, or adding the candidate drug, either directly or as a diluted solution, to the cultured product containing the keratinocytes and the culture medium.
  • Serine racemase is a racemase that is dependent on pyridoxal-5′ phosphate (PLP), a coenzyme of vitamin B6. While it is not intended to be constrained by theory, serine racemase is an enzyme capable of conversion between L-serine and D-serine via production of an anionic intermediate, by withdrawal of the α-hydrogen from serine. In the conversion reaction between L-serine and D-serine, there is no change in enthalpy before and after the reaction, and the reaction is driven by entropy. Therefore, L-serine and D-serine are equivalent in the equilibrium state. Since the abundance of L-serine is greater than D-serine in the body, the presence of serine racemase converts L-serine in the body to D-serine. Since the L-form is usually more abundant in culture medium even under culturing conditions, the presence of serine racemase similarly converts L-serine to D-serine. According to the invention, the racemase can be identical to the racemase found to be expressed in the brain according to NPL 3, or a homolog or ortholog thereof. Thus, it can be amplified by a primer pair used in that publication, and is detectable by the racemase antibody described in the same publication. Serine racemase can be identified by a person skilled in the art according to animal species, from the web site of an authorized institution such as NCBI.
  • According to one aspect of the invention, serine racemase activity in keratinocytes can be used as an indicator for evaluation of skin barrier function or for screening of skin barrier function enhancing agents. Serine racemase activity can generally be based on the amount of D-serine produced by conversion of L-serine in the culture medium, when a substance acting as the substrate for the enzyme is not added, or it may be based on the total amount of other D-amino acids including D-serine. Also, addition of a substance other than serine that can serve as a substrate for serine racemase may be carried out to measure the amount of product or measure the conversion efficiency, based on conversion of the additive. Since serine racemase converts excess optical isomer to the other optical isomers until the D-form and L-form ratio become 50:50, it is of course possible to add the D-form for activity measurement. In this case, evaluation of enzyme activity can be accomplished even by measuring the increase in L-serine produced by conversion. If a derivative of cycloserine or serine (such as the N-methylated form, acetylated form or phosphorylated form) is also added, it is possible to evaluate the enzyme activity by examining the conversion efficiency to the corresponding optical isomer. When serine racemase activity is to be measured based on the D-serine level, it may be determined by the abundance of D-serine in a skin sample isolated from a subject, or in cultured keratinocytes, i.e. in a culture medium, cells or both, or it may be determined by an enzymatic parameter determined based on the change in the abundance of D-serine in a skin sample or in cultured keratinocytes. This method is applicable to all of the aforementioned substances that can act as enzyme substrates. The enzymatic parameter representing serine racemase enzyme activity may be obtained by determining the Vmax or Km values.
  • According to another aspect of the present invention, the D-serine level in keratinocytes can be used as an indicator for evaluation of skin barrier function or for screening of skin barrier function enhancing agents. The D-serine level may be measured in a skin sample isolated from a subject, or in cultured keratinocytes, i.e. in a culture medium, cells or both. The method of measuring the D-serine level may be carried out using a known method. For example, it may be carried out by an HPLC method using an optical isomer separating column, or a gas chromatography, electrophoresis or enzyme method. When measurement of the serine racemase activity is carried out by measuring the D-serine level, L-serine may be added to the cultured keratinocytes to increase the D-serine level. When serine racemase catalyzes conversion reaction between L-serine and D-serine, the enthalpy before and after the reaction does not change, and the reaction is driven by entropy. Therefore addition of L-serine can increase the D-serine level in proportion to the serine racemase activity, and therefore measurement of the D-serine level becomes easier.
  • According to another aspect, serine racemase expression level can be used as an indicator for evaluation of skin barrier function or for screening of skin barrier function enhancing agents. The serine racemase expression level can be determined by measuring serine racemase protein by an immunological method using anti-serine racemase antibody. The immunological method can be carried out by Western blotting, fluorescent immunostaining or ELISA. The anti-serine racemase antibody used may be monoclonal antibody or polyclonal antibody, and it may be antibody collected by immunizing an experimental animal such as a rabbit or mouse with serine racemase protein or antigen peptide.
  • It can also be accomplished by determining the serine racemase expression level based on the amount of serine racemase mRNA in cells. The mRNA may be measured by any desired method, and for example, it can be measured based on a quantitative PCR method. A quantitative PCR method is usually conducted as follows, with the understanding that this is not limitative. The mRNA is extracted from collected cells, and cDNA is prepared using polyT primer and reverse transcriptase. The prepared cDNA may be subjected to the SYBR green method or fluorogenic probe method to quantify the amount of mRNA in the cells.
  • More specifically, the screening method of the invention may comprise the following steps:
  • adding a candidate drug to keratinocytes,
  • measuring the expression level or activity of serine racemase and/or the D-serine level in keratinocytes, and
  • determining the skin barrier function-enhancing effect of the candidate drug based on the expression level or activity of serine racemase and/or the D-serine level. The screening method of the invention may further comprise a step of inducing differentiation of keratinocytes.
  • The differentiation inducing step is carried out by subjecting keratinocytes to differentiation-inducing stimulation. Subjecting keratinocytes to differentiation-inducing stimulation results in cellular flattening, increase in intracellular fibers or granules, indistinct intercellular spaces, superpositioning (especially with monolayer cultures), and finally resulting in the morphological change of enucleation, or changes in cells that result in production of or changes in proteins such as keratin 1, keratin 10, involucrin or transglutaminase activation (see Nippi Kaishi, 90(12), 1089-1101, http://drmtl.org/data/090121089.pdf, Drug News Perspect 2004, 17(2) p 117). The differentiation-inducing stimulation may be any desired stimulation that can produce the aforementioned differentiation of keratinocytes, and may include, for example, stimulation of calcium ion that increases the calcium ion concentration, stimulation with phorbol-12-myristate-13-acetate (Hawley-Nelson P, Stanley J R et al, Exp Cell Res, 137: 155-167, 1982), physical stimulation by voltage or gas phase exposure, or stimulation with a biological solution. For stimulation with calcium ion, a calcium salt or its diluted solution may be added to a concentration of 0.1 mM to 10 mM as the final concentration of calcium ion, or the culture medium may be exchanged with medium already adjusted to a final concentration of calcium ion. The calcium salt used includes, for example, calcium chloride, calcium hydrogencarbonate, calcium carbonate, calcium nitrate or calcium acetate, etc. The upper limit for the final calcium ion concentration is preferably 5 mM and even more preferably 2 mM, from the viewpoint of not adversely affecting the cell culture. From the viewpoint of promoting the induced differentiation, the lower limit for the concentration is preferably 0.5 mM and more preferably 1.0 mM.
  • The differentiation-inducing step and the candidate drug addition step may be carried out simultaneously, the candidate drug addition step may be carried out after the differentiation-inducing step, or conversely the differentiation-inducing step may be carried out after the candidate drug addition step. While it is not intended to be limited to theory, the timing for inducing differentiation and adding candidate drugs can be varied depending on the action mechanism desired for the candidate drug. For example, from the viewpoint of examining antagonism of drugs with differentiation-inducing stimulation substances, the addition step is preferably carried out either simultaneously with or before the stimulation step. Also, from the viewpoint of promoting or inhibiting cellular changes (morphological changes, and expression of various intracellular factors) after differentiation has been induced, the addition step is preferably carried out simultaneously with or after the stimulating step, and from the viewpoint of illuminating mechanisms such as exploring mechanisms such as pre-blocking of receptors on which differentiation-inducing stimulation acts, the stimulating step is preferably carried out after the addition step. When the candidate drug addition step and the differentiation-inducing stimulation step are not carried out simultaneously, a cell culturing step of several minutes to several hours may be included between the addition step and the stimulation step.
  • After differentiation-inducing stimulation and candidate drug addition, a cell culturing step may be further included before the step of measuring the serine racemase expression level or activity and/or the D-serine level. The period for the cell culturing step can be selected as desired depending on the type and concentration of the differentiation-inducing agent used and the type of keratinocytes, and culturing may be conducted for 6 hours to 1 week, for example. From the viewpoint of adequately expressing serine racemase, the minimum culturing period is preferably 12 hours and more preferably 1 day. On the other hand, the maximum culturing period cannot be specified since it will differ depending on the culturing method, such as monolayer culturing, multi-layered culturing or three-dimensional culturing, but from the viewpoint of maintaining normal cell culturing conditions it is preferably no longer than one week and more preferably no longer than 3 days, for monolayer culturing.
  • The screening method of the invention may further include a damage-inducing step. The damage-inducing step may be inducement of damage by physical or chemical stimulation of the cultured keratinocytes, such as addition of a radical source such as ultraviolet irradiation or an oxidizing agent, addition of a surfactant, or exchange with oligotrophic medium. The keratinocytes that have been damaged by the damage-inducing step may be expected to have reduced serine racemase expression. Thus, in a screening method in which a damage-inducing step is carried out after the candidate drug addition step, if reduction in racemase expression level or racemase activity and/or D-serine level is found to be suppressed, the candidate drug can be used as a preventive drug against damage to skin barrier function. On the other hand, in a screening method in which a candidate drug addition step is carried out after a damage-inducing step, if reduced racemase expression level or racemase activity and/or D-serine level is found to be increased, the candidate drug can be used as a restoring, ameliorating or curative agent for skin barrier function. In a screening method where damage is not induced, a candidate drug that increases racemase expression level or racemase activity, and/or D-serine level, can be considered to be an enhancer of skin barrier function.
  • As a result of carrying out the screening method of the present invention, hydrolyzed oat protein, Lempuyang extract, Elephantopus mollis extract can be selected as an agent enhancing skin barrier function. However, such an agent is not limited to extract derived from Lempuyang and Elephantopus mollis, extract derived from related species has the skin barrier function enhancing effect in a similar way. The skin barrier function enhancing agent of the present invention include extract of a plant belonging to the genus Zingiber of Zingiberaceae family and a plant belonging to the Elephamtopus genus of Compositae family. Therefore, a cosmetic product exerting skin barrier function enhancing effect can be prepared by containing these substances in a cosmetic product.
  • The hydrolyzed oat protein used in the present invention is a hydrolyzate of protein obtained from oat (Avena sativa L.). While the protein of oat is extracted, for example, from seeds, leaves, roots, and from bran, the seeds are particularly preferred. The oat, which was immediately dried and ground after harvest, are preferred. It may be dried under the sun, or may be dried by using a drying machine that is normally used. The protein is hydrolyzed by the acid or enzyme treatment in the process of extraction or after extraction. Oats is a plant that is grown for food from West Asia to Europe and North America. The extraction solvent used in the present invention can be any solvent usually used for extraction. In particular, an organic solvent including alcohols such as methanol, ethanol, water-containing alcohols, acetone, ethyl acetate ester can be used for extraction alone or in combination. It is possible to perform the extraction with water.
  • The amount of the hydrolyzed oat protein of the present invention can be arbitrarily selected by a person skilled in the art within the scope exerting an effect. For example, the amount of the extract constitutes, as a dry composition, 0.0005-20.0 wt % of the total amount of the external formula The upper limit of the amount is preferably less than 10 wt % by weight or less, and more preferably 5 wt % or less from the viewpoint of exerting an effect and preparing a formulation. The lower limit of the amount is preferably 0.0001 wt % or more, more preferably 0.0005 wt % or more in view of exerting a sufficient skin barrier function enhancing effect.
  • Among plants belonging to the genus Zingiber of Zingiberaceae family, Lempuyang (Zingiber aromaticum Mal.) is preferable. Lempuyang is a plant growing dry grassland and pasture in particular in Indonesia. The extract used in the present invention is prepared by immersing foliage, stem including rhizomes, fruits, etc., of the plant and the whole plant in an extract solvent, optionally heating the mixture to reflux, then being subjected to filtration and concentration. The extraction solvent used in the present invention can be any solvent usually used for extraction. In particular, an organic solvent including alcohols such as methanol, ethanol, water-containing alcohols, acetone, ethyl acetate ester can be used for extraction alone or in combination. It is possible to perform the extraction with water.
  • The amount of the extract of a plant belonging to the genus Zingiber of Zingiberaceae family can be arbitrarily selected by a person skilled in the art within the scope exerting an effect. For example, the amount of the extract constitutes, as a dry composition, 0.0005-20.0 wt % of the total amount of the external formula The upper limit of the amount is preferably less than 10 wt % by weight or less, and more preferably 5 wt % or less from the viewpoint of exerting an effect and preparing a formulation. The lower limit of the amount is preferably 0.0001 wt % or more, more preferably 0.0005% wt % or more in view of exerting a sufficient skin barrier function enhancing effect.
  • Among a plant belonging to the genus Elephamtopus of Compositae family, Elephantopus mollis is preferable. Elephantopus mollis is an indigenous plant in Venezuela of South America, and has been widely naturalized in tropical Asia. The extract of a plant belonging to the genus Elephamtopus of Compositae family is prepared by immersing Leaves, stems, flowers, bark, seeds or fruit, etc., of the plant and the whole plant in an extract solvent, optionally heating the mixture to reflux, then being subjected to filtration and concentration. The extraction solvent used in the present invention can be any solvent usually used for extraction. In particular, an organic solvent including alcohols such as methanol, ethanol, water-containing alcohols, acetone, ethyl acetate ester can be used for extraction alone or in combination. It is possible to perform the extraction with water.
  • The amount of the extract of a plant belonging to the genus Elephamtopus of Compositae family can be arbitrarily selected by a person skilled in the art within the scope exerting an effect. For example, the amount of the extract constitutes, as a dry composition, 0.0005-20.0 wt % of the total amount of the external formula The upper limit of the amount is preferably less than 10 wt % by weight or less, and more preferably 5 wt % or less from the viewpoint of exerting an effect and preparing a formulation. The lower limit of the amount is preferably 0.0001 wt % or more, more preferably 0.0005% wt % or more in view of exerting a sufficient skin barrier function enhancing effect.
  • In a step of determining the skin barrier function-enhancing function of a candidate drug based on serine racemase expression level or activity, or D-serine level, it is possible to determine it based on the measured serine racemase expression level or activity and/or D-serine level using a preset table showing the relationship between expression level or activity and/or D-serine level and barrier function-enhancing function. Such a table can be prepared using racemase expression level or activity and/or D-serine level measured by a similar experiment without the candidate drug, as a control, or using racemase expression level or activity and/or D-serine level measured by a similar experiment using a control drug known to increase serine racemase expression level or activity and/or D-serine level. According to a different aspect, the skin barrier function-enhancing action of a candidate drug can be determined by setting a predetermined threshold value based on comparison with a control, and determining whether or not the effect is higher than the threshold value by a statistically significant difference. A person skilled in the art can appropriately set the threshold value according to the skin barrier function-enhancing effect that is desired. Such a threshold value may be a threshold value set to an arbitrary factor with respect to serine racemase expression level or activity and/or D-serine level for a control where the drug has not been added, and for example, the value may be set to a factor of 1.1, for example, by a statistically significant difference and marginal significant difference. A statistically significant difference is p<0.05, and a marginal significant difference is p<0.1. Also, according to yet a different mode, it may be determined that a skin barrier function-enhancing effect is exhibited in the case of high expression level or activity compared to the racemase expression level or activity and/or D-serine level measured by conducting a similar experiment without the candidate drug, as a control, in which case it can be determined that higher expression level or activity and/or D-serine level is a greater skin barrier function-enhancing effect.
  • According to yet another aspect, the invention relates to a method of evaluating, judging and discriminating skin barrier function using serine racemase expression level or activity and/or D-serine level as an indicator. Such evaluation, judgment or discrimination can be made by measuring D-serine content, serine racemase activity or serine racemase expression level for a skin sample such as a stratum corneum sample obtained by tape stripping, for example, from a subject. The method of evaluating, judging or discriminating skin barrier function will usually be carried out by measuring TEWL using a Vapometer. However, TEWL is dependent on the state of the skin and its numerical values vary depending on rinsing and abrasion, while in skin disease patients there is no definite correlation between the numerical values and skin health. The evaluation, judgment and discrimination method of the invention uses serine racemase activity or expression level and/or D-serine level as an indicator to allow measurement of the original cellular-level skin barrier function of skin.
  • Also, since the evaluation method of the invention determines the normalcy of skin barrier function on the cellular level, it allows prediction of future skin barrier function rather than current skin barrier function. The evaluation, judgment or discrimination of skin barrier function can be made using a table or threshold value representing the relationship between a previously set serine racemase expression level or activity and/or D-serine level, and barrier function-enhancing effect. Such a table or threshold value can be set based on expression level or activity and/or D-serine level obtained for a skin sample obtained and isolated from subject groups with healthy skin, subject groups with roughened skin, and from age-classified subject groups.
  • The present invention will now be explained in greater detail by the following examples. However, the invention is in no way limited by the examples.
    • EXAMPLES Example 1 Verification of Relationship Between D-Serine Content and Barrier Function in Stratum Corneum
  • The subjects were 57 volunteers having healthy test sites, and the test sites wetted by rinsing after cleaning by a prescribed method were allowed to stand for 30 minutes at constant temperature, constant humidity conditions (room temperature: 22° C., humidity: 45%). Next, the transepidermal water loss (TEWL) was measured with a Vapometer (Delfin Co.). Measurement was performed 3 times and the average value was subsequently used for analysis. Next, the stratum corneum at the TEWL-measured site was stripped twice using adhesive tape and the second was used for extraction of amino acids in a 95% methanol aqueous solution. The optical isomers of the extracted amino acids were analyzed by a reported method (reference: Yurika Miyoshi et al., Journal of Chromatography B, 877 (2009) 2506-2512). The results are summarized below. The extracted amino acids were subjected to fluorescent derivatization with 4-fluoro-7-nitro-2,1,3-benzooxadiazole (NBD-F) in a borate buffer (pH 8.0). After this derivatization, pH of the solution was adjusted to acidic conditions by adding trifluoroacetic acid. The derivatives were subjected two-dimensional Micro HPLC (Shiseido Corp.). For the first dimension there was used a micro monolithic ODS column (inner diameter: 0.53 mm, full lengths: 500, 750, 1000 mm, Shiseido Corp.), and for the second dimension there was used an optical resolution enantio-selective column (inner diameter: 1.5 mm, full length: 250 mm, mobile phase conditions were optimized for each amino acid). The NBD-amino acids were detected by fluorescence at 530 nm (excitation wavelength of 470 nm). The results are shown in Table 1 and FIG. 1.
  • TABLE 1
    High TEWL group Low TEWL group
    (=low barrier group) (=high barrier group)
    D-Ser L-Ser D-Ser L-Ser
    (fmol/ (fmol/ (fmol/ (fmol/
    in- injec- injec- injec-
    n TEWL jection) tion) TEWL tion) tion)
    Mean 10 69 97633 6 106 123496
    SE 0.23 11 16503 0.15 16 19546
    p-value in 0.013 0.146
    student's
    t-test
  • In order to verify the relationship between D-serine (D-Ser) content and skin barrier function in the stratum corneum, the subjects were ordered according to TEWL value, and the D-serine contents in the stratum corneum were compared between the top 17 (inferior barrier function group) and bottom 17 (superior barrier function group). The significant difference between the two groups was verified by a non-paired Student's t-test. The results demonstrated that humans with high skin barrier function had significantly high D-serine contents. On the other hand, results of comparison for L-serine indicated a tendency toward lower L-serine content in the inferior barrier function group and higher L-serine content in the superior barrier function group, although the difference was not significant. Thus, it may be concluded that the high D-serine content in the superior barrier function group was not due to the amount of L-serine as the precursor, but rather to racemase expression and activity.
    • Example 2 Variation in D-Serine Content with Induced Differentiation of Keratinocytes Cell Culturing and Drug Preparation
  • Normal human keratinocytes were seeded in a 24 well multiplate to a cell density of 2.5×104 cells/well, and cultured in KGM culture medium (Kurabo Industries, Ltd.) under conditions of 37° C., 5% CO2. After 3 days, the medium was exchanged with KGM culture medium to which 1.8 mM calcium chloride and 10 mM L-serine had been added (test group), or KGM culture medium to which 10 mM L-serine alone had been added (control group), and culturing was continued for another 2 days.
    • HPLC Sample Preparation and Free D-Serine Analysis by HPLC.
  • After rinsing cells with PBS, 500 μL of a 5% trichloroacetic acid aqueous solution was added, the cells were thoroughly dispersed and recovered, and ultrasonic treatment was performed for 30 minutes on ice, after which centrifugal separation was performed to obtain a supernatant. The amino acids in the supernatant were extracted by addition of a 20-fold amount of methanol. The optical isomers of the extracted amino acids were analyzed by a reported method (reference: Yurika Miyoshi et al., Journal of Chromatography B, 877 (2009) 2506-2512). The results are summarized below. The extracted amino acids were subjected to fluorescent derivatization with 4-fluoro-7-nitro-2,1,3-benzooxadiazole (NBD-F) in a borate buffer (pH 8.0). After this derivatization, pH of the solution was adjusted to acidic conditions by adding trifluoroacetic acid. The derivatives were subjected to two-dimensional Micro HPLC (Shiseido Corp.). For the first dimension there was used a micro monolithic ODS column (inner diameter: 0.53 mm, full length: 750 mm, Shiseido Corp.), and for the second dimensional optical resolution, there was used an optical resolution enantio-selective column inner diameter: 1.5 mm, full length: 250 mm, mobile phase conditions were optimized for each amino acid). The NBD-amino acids were detected by fluorescence at 530 nm (excitation wavelength of 470 nm). The results for the test group and control group are shown in FIG. 2.
    • Example 3 Screening of Candidate Drugs Cell Culturing and Drug Preparation
  • Normal human keratinocytes were seeded in a 24 well multiplate to a cell density of 2.5×104 cells/well, and cultured in KGM culture medium (Kurabo Industries, Ltd.) under conditions of 37° C., 5% CO2. After 3 days, the medium was exchanged with KGM culture medium containing 1.8 mM calcium chloride, 10 mM L-serine and the candidate drug diluted solution, and culturing was continued for another 2 days. Seven drugs were used as candidate drugs, of which one was a 0.5% hydrolyzed oat protein solution.
    • HPLC Sample Preparation and Free D-Serine Analysis by HPLC.
  • After rinsing cells with PBS, 500 μL of a 5% trichloroacetic acid aqueous solution was added, the cells were thoroughly dispersed and recovered, and ultrasonic treatment was performed for 30 minutes on ice, after which centrifugal separation was performed to obtain a supernatant. The amino acids in the supernatant were extracted by addition of a 20-fold amount of methanol. The optical isomers of the extracted amino acids were analyzed by a reported method (reference: Yurika Miyoshi et al., Journal of Chromatography B, 877 (2009) 2506-2512). The results are summarized below. The extracted amino acids were subjected to fluorescent derivatization with 4-fluoro-7-nitro-2,1,3-benzooxadiazole (NBD-F) in a borate buffer (pH 8.0). After this derivatization, pH of the solution was adjusted to acidic conditions by adding trifluoroacetic acid. The derivatives were subjected to two-dimensional Micro HPLC (Shiseido Corp.). For the first dimension there was used a micro monolithic ODS column (inner diameter: 0.53 mm, full length: 750 mm, Shiseido Corp.), and for the second dimensional optical resolution, there was used an optical resolution enantio-selective column (inner diameter: 1.5 mm, full length: 250 mm, mobile phase conditions were optimized for each amino acid). The NBD-amino acids were detected by fluorescence at 530 nm (excitation wavelength of 470 nm). The results are shown in Table 2 and FIG. 3A below.
    • Quantitative PCR (RT-PCR)
  • After rinsing cells with PBS, MagNA Pure LC (Roche Diagnostic Corp.) was used to extract the mRNA from the cells. Next, a reverse transcriptase SuperScriptVILO (Invitrogen Corp.) kit was used to synthesize cDNA. The cDNA was used as template for real-time PCR using fluorescent dye CyberGreen with a LightCycler (Roche Diagnostic Corp.). The PCR reaction was enzyme activation at 95° C. for 10 minutes followed by amplification reaction at 95° C. for 15 seconds, 60° C. for 10 seconds and 72° C. for 10 seconds, repeated 30 times. The gene expression level was calculated as a relative value from the number of cycles until a unit PCR product was obtained. RT-PCR was conducted with the G3PDH (glyceraldehyde-3-phosphate) gene as the internal standard in addition to the serine racemase gene, and the drug evaluation was conducted by correlating the relative expression level of serine racemase with the relative expression level of G3PDH. The primers selected for use in RT-PCR were those described in NPL 3 and NPL 4. The results are shown in Table 2 and FIG. 3B below.
  • TABLE 2
    PCR results
    SR D-Serine content
    SR expression p value SR content
    SR expression SD (VS SR content SD p value
    expression/ (% control L- (% control control) (% control (% control (VS control)
    G3PDH Ser(+)) L-Ser(+)) Student's t L-Ser(+)) L-Ser(+)) Student's t
    Control 100.00 3.50 100.00 19.40
    Oat protein 151.94 37.30 0.074 119.09 3.43 0.063
  • Of the candidate drugs supplied for this screening, the hydrolyzed oat protein solution promoted serine racemase expression in differentiation-induced keratinocytes. It was also shown that hydrolyzed oat protein solution increases the D-serine content in differentiation-induced keratinocytes. Based on these results, hydrolyzed oat protein solution can be selected as an effective drug for enhancing skin barrier function.
    • Example 4 Screening of Candidate Drugs Cell Culturing and Drug Preparation
  • Normal human keratinocytes were seeded in a 24 well multiplate to a cell density of 2.5×104 cells/well, and cultured in KGM culture medium (Kurabo Industries, Ltd.) under conditions of 37° C., 5% CO2. After 3 days, the medium was exchanged with KGM culture medium containing 1.8 mM calcium chloride, 10 mM L-serine and the candidate drug diluted solution, and culturing was continued for another 2 days. 12 drugs were used as candidate drugs, in which 0.5% Lempuyang extract and 0.5% Elephantopus mollis extract were included.
    • Quantitative PCR (RT-PCR)
  • After rinsing cells with PBS, MagNA Pure LC(Roche Diagnostic Corp.) was used to extract the mRNA from the cells. Next, a reverse transcriptase SuperScriptVILO (Invitrogen Corp.) kit was used to synthesize cDNA. The cDNA was used as template for real-time PCR using fluorescent dye CyberGreen with a LightCycler (Roche Diagnostic Corp.). The PCR reaction was enzyme activation at 95° C. for 10 minutes followed by amplification reaction at 95° C. for 15 seconds, 60° C. for 10 seconds and 72° C. for 10 seconds, repeated 30 times. The gene expression level was calculated as a relative value from the number of cycles until a unit PCR product was obtained. RT-PCR was conducted with the G3PDH (glyceraldehyde-3-phosphate) gene as the internal standard in addition to the serine racemase gene, and the drug evaluation was conducted by correlating the relative expression level of serine racemase with the relative expression level of G3PDH. The primers selected for use in RT-PCR were those described in NPL 3 and NPL 4. The results are shown in Table 3 below.
  • TABLE 3
    PCR results
    Serine
    Serine Racemase
    Serine Racemase expression p value
    Racemase expression SD (VS
    expression/ (% control L- (% control control)
    G3PDH Ser(+)) L-Ser(+)) Student's t
    Control 100.00 36.50
    Lempuyang 170.02 36.18 0.068
    extract
    Elephantopus 173.07 15.90 0.011
    mollis
    extract
  • Of the candidate drugs supplied for this screening, Lempuyang extract and Elephantopus mollis extract promoted serine racemase expression in differentiation-induced keratinocytes. Based on this result, Lempuyang extract and Elephantopus mollis extract can be selected as an effective drug for enhancing skin barrier function.

Claims (11)

What is claimed is:
1. A method for screening a skin barrier function enhancing agent, using the activity or expression level of serine racemase and/or D-serine level in keratinocytes as an indicator.
2. The screening method according to claim 1, comprising:
adding a candidate drug to keratinocytes;
measuring the activity or expression level of serine racemase and/or the D-serine level in the keratinocytes; and
determining the skin barrier function enhancing effect of the candidate drug based on the activity or expression level of serine racemase and/or the D-serine level.
3. The screening method according to claim 2, further comprising a step of inducing differentiation of the keratinocytes.
4. The screening method according to claim 3, wherein the screening method is conducted in the differentiation-induced keratinocytes.
5. The screening method according to claim 1, wherein the measurement of the serine racemase expression level is carried out by measuring the amount of serine racemase mRNA or protein.
6. The screening method according to claim 1, wherein the measurement of serine racemase activity is carried out by measuring the substrate conversion efficiency by serine racemase, or measuring the amount of D-amino acid product.
7. A serine racemase activating agent comprising one or more substances selected from the group consisting of hydrolyzed oat protein, Lempuyang extract, and Elephantopus mollis extract as an active ingredient, which is obtained by the screening method according to claim 1.
8. A method for evaluating a skin barrier function, using an activity or expression level of serine racemase and/or D-serine level from a skin sample isolated from human skin as an indicator.
9. The skin barrier function evaluation method according to claim 8, comprising:
measuring the activity or expression level of serine racemase and/or D-serine level in a skin sample isolated from a subject, and
determining the skin barrier function of the subject from the activity or expression level of serine racemase and/or D-serine level.
10. The skin barrier function evaluation method according to claim 8, wherein measurement of the serine racemase expression level is carried out by measuring amounts of mRNA or protein of serine racemase.
11. The method according to claim 8, wherein the measurement of serine racemase activity is carried out by measuring the substrate conversion efficiency or amount of D-amino acid product by serine racemase.
US14/477,213 2014-03-05 2014-09-04 Method for screening skin barrier function enhancing agent based on epidermal serine racemase and/or d-serine level, and skin barrier function evaluation method Abandoned US20160069867A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US14/477,213 US20160069867A1 (en) 2014-09-04 2014-09-04 Method for screening skin barrier function enhancing agent based on epidermal serine racemase and/or d-serine level, and skin barrier function evaluation method
PCT/JP2015/056570 WO2015133591A1 (en) 2014-03-05 2015-03-05 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or d-serine level as indicator
KR1020167024424A KR20160127751A (en) 2014-03-05 2015-03-05 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or d-serine level as indicator
US15/123,274 US10337064B2 (en) 2014-03-05 2015-03-05 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or D-serine level as indicator
US16/412,993 US10907208B2 (en) 2014-03-05 2019-05-15 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or D-serine level as indicator
US17/130,886 US20210189487A1 (en) 2014-03-05 2020-12-22 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or d-serine level as indicator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/477,213 US20160069867A1 (en) 2014-09-04 2014-09-04 Method for screening skin barrier function enhancing agent based on epidermal serine racemase and/or d-serine level, and skin barrier function evaluation method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/055680 Continuation WO2015132917A1 (en) 2014-03-05 2014-03-05 Method for screening skin barrier function-enhancing drug and method for evaluating skin barrier function having epidermal serine racemase and/or d-serine quantity as indicator

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2014/055680 Continuation WO2015132917A1 (en) 2014-03-05 2014-03-05 Method for screening skin barrier function-enhancing drug and method for evaluating skin barrier function having epidermal serine racemase and/or d-serine quantity as indicator
US15/123,274 Continuation US10337064B2 (en) 2014-03-05 2015-03-05 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or D-serine level as indicator

Publications (1)

Publication Number Publication Date
US20160069867A1 true US20160069867A1 (en) 2016-03-10

Family

ID=55437292

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/477,213 Abandoned US20160069867A1 (en) 2014-03-05 2014-09-04 Method for screening skin barrier function enhancing agent based on epidermal serine racemase and/or d-serine level, and skin barrier function evaluation method
US15/123,274 Active US10337064B2 (en) 2014-03-05 2015-03-05 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or D-serine level as indicator
US16/412,993 Active US10907208B2 (en) 2014-03-05 2019-05-15 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or D-serine level as indicator
US17/130,886 Abandoned US20210189487A1 (en) 2014-03-05 2020-12-22 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or d-serine level as indicator

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/123,274 Active US10337064B2 (en) 2014-03-05 2015-03-05 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or D-serine level as indicator
US16/412,993 Active US10907208B2 (en) 2014-03-05 2019-05-15 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or D-serine level as indicator
US17/130,886 Abandoned US20210189487A1 (en) 2014-03-05 2020-12-22 Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or d-serine level as indicator

Country Status (1)

Country Link
US (4) US20160069867A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585194A (en) * 2019-10-12 2019-12-20 广州医科大学附属第五医院 Application of sesquiterpene lactone compounds in preparation of lysosome autophagy inhibitor and anti-cancer drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981681A (en) * 1988-08-26 1991-01-01 Vittorio Tosti Lotion mixture and method of treating psoriasis
US7235249B2 (en) * 2002-03-28 2007-06-26 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions
US7758878B2 (en) 2003-10-10 2010-07-20 Access Business Group International Llc Cosmetic treatment system and methods
KR20060108665A (en) 2003-10-10 2006-10-18 액세스 비지니스 그룹 인터내셔날 엘엘씨 Composition comprising a rosmarinus officinalis plant extract, a centella, echinacea or alpinia plant extract and a dna repair enzyme
WO2005044214A1 (en) * 2003-11-06 2005-05-19 Unilever Plc Improved cosmetic composition comprising vitamin b3, vitamin b6 and an organic acid
EP1792599A4 (en) * 2004-09-24 2012-07-11 Shiseido Co Ltd Whitening agent
US20120148509A1 (en) 2009-09-14 2012-06-14 Shiseido Company, Ltd. Composition for alleviating ultraviolet irradiation-induced damage
JP2012092032A (en) 2010-10-26 2012-05-17 Unitika Ltd Ceramide production promoter

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585194A (en) * 2019-10-12 2019-12-20 广州医科大学附属第五医院 Application of sesquiterpene lactone compounds in preparation of lysosome autophagy inhibitor and anti-cancer drugs

Also Published As

Publication number Publication date
US20210189487A1 (en) 2021-06-24
US20190300953A1 (en) 2019-10-03
US10337064B2 (en) 2019-07-02
US20170073751A1 (en) 2017-03-16
US10907208B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
JP6934925B2 (en) Serine racemase activator and skin barrier enhancer
Pandit et al. Separation of an effective fraction from turmeric against Streptococcus mutans biofilms by the comparison of curcuminoid content and anti-acidogenic activity
Furse et al. The lipidome and proteome of oil bodies from Helianthus annuus (common sunflower)
Andoh et al. Expression of BLT1 leukotriene B4 receptor on the dorsal root ganglion neurons in mice
Prastya et al. Antioxidant, antiglycation and in vivo antiaging effects of metabolite extracts from marine sponge-associated bacteria
Qiu et al. Stimulation of glucose uptake by theasinensins through the AMP-activated protein kinase pathway in rat skeletal muscle cells
KR20130134976A (en) A cosmetic composition for whitening skin containing cynanchum atratum extracts
EP2618808B1 (en) Cosmetic use of dermicidin and fragments thereof
EP3475697B1 (en) Juvenile atopic dermatitis models
Piccolella et al. Recovering Cucurbita pepo cv.‘Lungo Fiorentino’Wastes: UHPLC-HRMS/MS metabolic profile, the basis for establishing their nutra-and cosmeceutical valorisation
Piccolo et al. Induction of hair keratins expression by an annurca apple-based nutraceutical formulation in human follicular cells
US20210189487A1 (en) Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or d-serine level as indicator
JP5737663B2 (en) Skin barrier function improver
JP7116589B2 (en) Composition for promoting Discoidin Domain Receptor2 (DDR2) production
CN112089638B (en) Composition for inhibiting melanin synthesis
Meunier et al. From stem cells protection to skin microbiota balance: Orobanche rapum extract, a new natural strategy
JP2011115152A (en) Screening method
WO2015132917A1 (en) Method for screening skin barrier function-enhancing drug and method for evaluating skin barrier function having epidermal serine racemase and/or d-serine quantity as indicator
WO2015133591A1 (en) Method for screening agents promoting skin barrier function and method for evaluating skin barrier function taking epidermal serine racemase and/or d-serine level as indicator
TWI666444B (en) Screening method for skin barrier function promoting agent and skin barrier function evaluation method using epidermal serine racemase and/or D-serine amount as indicators
KR20160028736A (en) Method for screening skin barrier function-enhancing medicament and method for evaluating skin barrier function, utilizing epidermal serine racemase and/or amount of d-serine as indication
JP2013257347A (en) Screening method and antiaging composition
JP6113981B2 (en) Screening method
Baumann et al. Nutritional supplementation of an apple callus extract to target epidermal aging
Cho et al. Propolis suppresses atopic dermatitis through targeting the MKK4 pathway

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHISEIDO COMPANY, LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TOJO, YOSUKE;IINO, MASATO;MIZUMOTO, CHIEKO;AND OTHERS;REEL/FRAME:033669/0863

Effective date: 20140827

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION